Form 4: Arcellx Chief Medical Officer Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Arcellx's Chief Medical Officer, Christopher Heery, sold a portion of his shares to cover tax obligations following the vesting of restricted stock units.
Summary
- Christopher Heery, the Chief Medical Officer of Arcellx, Inc., engaged in several transactions involving the company's stock.
- On January 3, 2025, 16,519 restricted stock units (RSUs) vested, converting into common stock.
- To cover tax obligations related to the vesting, Mr. Heery sold 4,230 shares on January 7, 2025, at an average price of $75.5283 per share.
- He further sold 3,553 shares on January 8, 2025, at an average price of $73.6929 per share.
- Following these transactions, Mr. Heery directly owns 25,085 shares of Arcellx common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It does not indicate any positive or negative sentiment towards the company's performance or future prospects.
Industry Context
This is a routine filing related to insider transactions, specifically the sale of shares by a company executive to cover tax obligations after the vesting of restricted stock units. Such transactions are common and do not necessarily indicate a change in the executive's outlook on the company's future.
Comparison to Industry Standards
- The sale of shares by executives to cover tax obligations after RSU vesting is a common practice across the industry.
- The reported prices are within the range of typical market fluctuations for a company like Arcellx.
- Similar transactions are regularly reported by executives at comparable biotech companies.
Stakeholder Impact
- The share sales may have a minor impact on the stock price, but are unlikely to significantly affect shareholders.
- The transactions are part of the executive's compensation package and do not directly impact employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | RSU Grant Date |
| 01/03/2025 | Restricted stock units vested and converted to common stock |
| 01/07/2025 | 4,230 shares sold to cover tax obligations |
| 01/08/2025 | 3,553 shares sold to cover tax obligations |
| 01/10/2025 | Date of filing the SEC Form 4 |
Keywords
Arcellx, Christopher Heery, Chief Medical Officer, stock sale, restricted stock units, RSU, tax obligations, insider trading, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.